Antiemetic use of olanzapine in patients with advanced cancer: results from an open-label multicenter study.
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Introduction The antipsychotic drug olanzapine is effective against chemotherapy-induced nausea and targets multiple receptors known to be involved in the emetic reflex arch. The drug has a mean half-life of 30 h, which allows for a single daily administration and is therefore of interest in patients with advanced cancer suffering from nausea. Objectives To investigate the antiemetic effect and tolerability of olanzapine in patients with advanced cancer not receiving chemotherapy or irradiation. Methods Patients with advanced cancer (no curable treatment options) with at least "moderate" nausea and/or one emetic episode within the last 24 h were included if they had not received chemotherapy or irradiation (last 2 weeks) and had no reversible causes of nausea/vomiting. Patients were administered 10 mg olanzapine daily for 5 days (the first day subcutaneously and the following 4 days orally). Nausea, vomiting, and adverse effects were assessed daily for 7 days. The primary efficacy parameter was nausea after 24 h. Results Forty patients from four centers were included and all evaluable after 24 h. Thirty-six patients experienced some degree of improvement. The mean two-item N/V score (0-100) at baseline was 66 and improved to 21 and 24 after 24 h and 7 days, respectively. During the course of the study, the dose of olanzapine was reduced in three patients due to adverse events. Five patients were withdrawn from the study primarily due to progression of malignant disease or per…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The magnitude of benefit observed in this trial, regarding nausea/vomiting, is in line with what has been reported in 3 other pilot reports.8,12,13”
From Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial (2020) · cites this paper as [12]
Citations
Cites
Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P., & Wong, D. T. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00129-n · Cited by 1,062
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Basch, E., Prestrud, A. A., Hesketh, P. J., Kris, M. G., Feyer, P. C., Somerfield, M. R., Chesney, M., Clark-Snow, R. A., Flaherty, A. M., Freundlich, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4614 · Cited by 1,059
Groenvold, M., Petersen, M. A., Aaronson, N. K., Arraras, J. I., Blazeby, J. M., Bottomley, A., Fayers, P. M., de Graeff, A., Hammerlid, E., Kaasa, S., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.06.022 · Cited by 678
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Hesketh, P. J., Kris, M. G., Basch, E., Bohlke, K., Barbour, S. Y., Clark-Snow, R. A., Danso, M. A., Dennis, K., Dupuis, L. L., Dusetzina, S. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.4789 · Cited by 628
Olanzapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Hunger, H., Schmid, F., Schwarz, S., Duggan, L., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006654.pub2 · Cited by 365
NCCN Guidelines Insights: Antiemesis, Version 2.2017
Berger, M. J., Ettinger, D. S., Aston, J., Barbour, S., Bergsbaken, J., Bierman, P. J., Brandt, D., Dolan, D. E., Ellis, G., Kim, E. J., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0117 · Cited by 252
Treating nausea and vomiting in palliative care: a review
Glare, P., Miller, J., Nikolova, & Tickoo (2011) · Clinical Interventions in Aging · doi:10.2147/cia.s13109 · Cited by 165
Passik, S. D., Lundberg, J., Kirsh, K. L., Theobald, D., Donaghy, K., Holtsclaw, E., Cooper, M., & Dugan, W. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00391-3 · Cited by 154
Herrstedt, J., Roila, F., Warr, D. G., Celio, L., Navari, R. M., Hesketh, P. J., Chan, A., & Aapro, M. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3313-0 · Cited by 122
Self-citationThe EORTC CAT Core—The computer adaptive version of the EORTC QLQ-C30 questionnaire
Petersen, M. A., Aaronson, N. K., Arrarás, J. I., Chie, W., Conroy, T., Costantini, A., Dirven, L., Fayers, P. M., Gamper, E., Giesinger, J. M., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.04.016 · Cited by 110
Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer.
Srivastava, M., Brito-Dellan, N., Davis, M. P., Leach, M., & Lagman, R. (2003) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(03)00143-x · Cited by 106
Boettger, S., Jenewein, J., & Breitbart, W. (2015) · Palliative and Supportive Care · doi:10.1017/s1478951514001059 · Cited by 106
Passik, S. D., Navari, R. M., Jung, S.-H., Nagy, C., Vinson, J., Kirsh, K. L., & Loehrer, P. (2004) · Cancer Investigation · doi:10.1081/cnv-200029066 · Cited by 102
Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial.
Navari, R. M., & Brenner, M. C. (2010) · Supportive Care in Cancer · doi:10.1007/s00520-009-0739-7 · Cited by 99
Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults
Sutherland, A., Naessens, K., Plugge, E., Ware, L., Head, K., Burton, M. J., & Wee, B. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012555.pub2 · Cited by 94
Walsh, D., Davis, M. P., Ripamonti, C. I., Bruera, E. D., Davies, A. N., & Molassiotis, A. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3371-3 · Cited by 93
Olanzapine for intractable nausea in palliative care patients.
Jackson, W. C., & Tavernier, L. (2003) · Journal of Palliative Medicine · doi:10.1089/109662103764978506 · Cited by 78
Yanai, T., Iwasa, S., Hashimoto, H., Ohyanagi, F., Takiguchi, T., Takeda, K., Nakao, M., Sakai, H., Nakayama, T., Minato, K., et al. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1200-4 · Cited by 74
Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review
Hocking, C. M., & Kichenadasse, G. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2138-y · Cited by 70
Markowitz, J. S., DeVane, C. L., Malcolm, R. J., Gefroh, H. A., Wang, J., Zhu, H., & Donovan, J. L. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005283839 · Cited by 66
Kaneishi, K., Kawabata, M., & Morita, T. (2012) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2011.10.023 · Cited by 58
Elsayem, A. F., Bush, S. H., Munsell, M. F., Curry, E. A., Calderon, B. B., Paraskevopoulos, T., Fadul, N. A., & Bruera, E. D. (2010) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2010.02.017 · Cited by 55
MacKintosh, D. (2016) · Journal of Palliative Medicine · doi:10.1089/jpm.2015.0224 · Cited by 33
Fonte, C., Fatigoni, S., & Roila, F. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.02.010 · Cited by 33
Atkinson, S. R. (2014) · Journal of Palliative Medicine · doi:10.1089/jpm.2014.0030 · Cited by 26
Suzuki, M., Komuro, K., & Ohara, K. (2014) · Case Reports in Gastroenterology · doi:10.1159/000358044 · Cited by 25
Selegiline orally disintegrating tablet in the treatment of Parkinsons disease
Clarke, A., & Jankovic, J. J. (2006) · Therapy · doi:10.2217/14750708.3.3.349 · Cited by 22
Kaneishi, K., Nishimura, K., Sakurai, N., Imai, K., Matsuo, N., Takahashi, N., Okamoto, K., Suga, A., Sano, H., Maeda, I., et al. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3101-x · Cited by 18
Bun, S., Yonemori, K., Akagi, T., Noguchi, E., Shimoi, T., Shimomura, A., Yunokawa, M., Shimizu, C., Fujiwara, Y., Makino, Y., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0487-3 · Cited by 7
Kitada, T., Narimatsu, T., & Yamaguchi, S. (2009) · Kanzo · doi:10.2957/kanzo.50.153 · Cited by 3
Murakami, N., Tanabe, K., Yamatani, K., Kitazawa, H., Fujikawa, Y., Amemiya, Y., Shimada, M., & Kadoya, S. (2012) · PubMed · Cited by 2
Research works printed but not linked: 2
- Shinjo T, Okada M (2006) Olanzapine use in cancer patients for refractory vomiting. Gan To Kagaku Ryoho 33(3):349–352
- Dev R (2018) Intractable nausea and anorexia with weight loss in a patient with advanced breast cancer. J Cachexia Sarcopenia Muscle 9(1):203
Cited by
Navari, R. M., Pywell, C. M., Le-Rademacher, J. G., White, P., Dodge, A. B., Albany, C., & Loprinzi, C. L. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.1052 · Cited by 78
Zhang, X., & Ying, J.-E. (2022) · Current Oncology · doi:10.3390/curroncol29110650 · Cited by 17
Nausea and Vomiting Not Related to Cancer Therapy: Intractable Problem or Clinical Challenge?
Wickham, R. (2020) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2020.11.5.4 · Cited by 16
The Management of Nausea and Vomiting Not Related to Anticancer Therapy in Patients with Cancer
Hardy, J. R., & Davis, M. P. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00813-0 · Cited by 15
Dev, R., Fortuno, E. S., Amaram‐Davila, J., Haider, A., & Bruera, E. D. (2023) · Annals of Palliative Medicine · doi:10.21037/apm-22-1167 · Cited by 15
Metadata
- Authors
- Harder, S., Groenvold, M., Isaksen, J., Sigaard, J., Frandsen, K. B., Neergaard, M. A., Mondrup, L., & Herrstedt, J.
- Affiliations
- University of Southern Denmark (DK)
- Odense University Hospital (DK)
- Hospital South West Jutland (DK)
- Frederiksberg Hospital (DK)
- Aarhus University Hospital (DK)
- University of Copenhagen (DK)
- Corresponding author
- Harder, Signe
- Venue
- Supportive Care in Cancer
- Published
- 2018-12-14
- Volume
- 27
- Issue
- 8
- Pages
- 2849-2856
- ISSN
- 0941-4355 (ISSN-L)
- 1433-7339
- OpenAlex
- W2904007992
- Semantic Scholar
- 510825b157fb5b78eb015f5b1b64cc6c8b24af23
- Cited by
- 17
- References
- 31
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 2 · 2022: 4 · 2021: 4 · 2020: 3 · 2019: 1
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Supportive Care in Cancer (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Kræftens Bekæmpelse (R56-A3126)
- IMK foundation (None)
- Odense Universitetshospital (None)
- Topics
- Health Sciences › Medicine › Surgery › Nausea and vomiting management
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Palliative and Oncologic Care
- Keywords
- olanzapine, antiemetic effect, nausea, vomiting, advanced cancer, antipsychotic drugs, emetic reflex, tolerability, adverse effects
- MeSH terms
- Olanzapine, Adult, Aged, Antiemetics, Female, Humans, Male, Middle Aged, Nausea, Neoplasms, Antipsychotic Agents, Vomiting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.